Comparison of the cost-effectiveness of sequential treatment with abaloparatide in US men and women at very high risk of fractures.

ABSTRACT:

Background

Osteoporotic-related fractures represent an increasing burden to patients, health care systems and society.

Aims

This study estimated cost-effectiveness of sequential treatment with abaloparatide (ABL) followed by alendronate (ALN) compared to relevant alternative strategies in US men and women aged 50 to 80 years at very high fracture risk (bone mineral density T-score ≤  - 2.5 and a recent fracture).

Methods

A lifetime Markov-based microsimulation model was used to estimate healthcare costs and quality-adjusted life years (QALYs). Comparators were sequential treatment with unbranded teriparatide (TPTD)/ALN, generic ALN monotherapy, and no treatment. Analyses were conducted based on initial fracture site (hip, vertebral, or any fracture) and treatment effi

SUBMITTER: Hiligsmann M 

PROVIDER: S-EPMC10827834 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature